Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh, 3459 Fifth Avenue, N755 MUH, Pittsburgh, PA 15213, USA. fungj@ccf.org
Although calcineurin inhibitors (CNIs) remain the mainstay of immunosuppression in liver transplantation (LTX), their long-term toxicity significantly contributes to morbidity and mortality. The elucidation of mechanisms of alloimmunity and leukocyte migration have provided novel targets for immunosuppression development. The toxicities of these agents differ from that of the CNI and act additively or synergistically. CNI avoidance protocols in LTX have not been achieved routinely; however, pilot trials have begun to delineate the limitations and promises of such approaches. CNI-sparing protocols appear to be much more promising in balancing the early need for minimizing rejection while tapering doses and minimizing long-term toxicity.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on